Abstract | AIMS: METHODS: Youth (n = 89) and adults (n = 132) were randomized to 3 months glargine followed by 9 months metformin (G/M) or 12 months metformin (MET). Insulin sensitivity and β-cell responses were estimated from 3-hour OGTTs over 21 months. Linear mixed models tested for differences by time and age group within each treatment arm. RESULTS:
After treatment withdrawal, HbA1c increased in both youth and adults with a larger net increase in G/M youth vs. adults at 21 months. Among youth, β-cell function decreased starting at 12 months in G/M and 15 months in MET. Among adults, β-cell function remained relatively stable although insulin secretion rates decreased in G/M at 21 months. At 21 months vs. baseline β-cell function declined to a greater extent in youth vs. adults in both the G/M and MET treatment arms. CONCLUSIONS:
After treatment withdrawal youth demonstrated progressive decline in β-cell function after stopping treatment with either G/M or MET. In contrast, β-cell function in adults remained stable despite an increase in HbA1c over time. ClinicalTrials.gov Identifier: NCT01779375 and NCT01779362 at clinical trials.gov.
|
Authors | Kristina M Utzschneider, Mark T Tripputi, Alexandra Kozedub, Elena Barengolts, Sonia Caprio, Melanie Cree-Green, Sharon L Edelstein, Laure El Ghormli, Tamara S Hannon, Kieren J Mather, Jerry Palmer, Kristen J Nadeau, RISE Consortium |
Journal | Diabetes research and clinical practice
(Diabetes Res Clin Pract)
Vol. 178
Pg. 108948
(Aug 2021)
ISSN: 1872-8227 [Electronic] Ireland |
PMID | 34274407
(Publication Type: Journal Article, Randomized Controlled Trial)
|
Copyright | Copyright © 2021 Elsevier B.V. All rights reserved. |
Chemical References |
|
Topics |
- Adolescent
- Adult
- Blood Glucose
- Diabetes Mellitus, Type 2
(drug therapy)
- Glucose Intolerance
- Glucose Tolerance Test
- Humans
- Insulin
(metabolism)
- Insulin Resistance
- Insulin Secretion
|